PATENT CLAIM ANALYSIS

Application Number: 16298902
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-06
Patent Classification: ["514", "011800"]

Abstract:
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 , wherein the X 1  subunit comprises a thiol-containing moiety and the distribution of charge on the X 2 -X 7  subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Claim (Index 9):
The compound of any one of  claims 1 - 4 , wherein the compound is Ac-D-penicillamin-rrrrrr-NH 2  (SEQ ID NO: 33).

Metadata:
- Claim Count in Document: 1.0
- Percentile: 99.0
- Lexical Diversity: 1.65823
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13769744', '15018567', '12846724', '13365213', '14639020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8625007311928448
- 35 USC 102 Novelty (BERT): 0.6178641803843897
- Combined Prediction Score: 0.8380370761119993
- Mean Citation Score: 665.45545
- Max Citation Score: 681.052
- Similarity Product: 489.0213936874866

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test